ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1331

Mathematical Model To Predict The Early Responders In a Monocentric Cohort Of Patients With Rheumatoid Arthritis Treated By Anti TNF-Alpha

Camillo Giacomelli1, Claudia Ferrari1, Chiara Stagnaro2, Rosaria Talarico3, Arianna Consensi1, Francesca Sernissi1, Laura Bazzichi1 and Stefano Bombardieri1, 1University of Pisa, Rheumatology Unit, Pisa, Italy, 2Rheumatology Unit, University of Pisa, Pisa, Italy, 3Rheumatology Unit, Pisa, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Anti-TNF therapy and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects II: Predictors of Disease Course in Rheumatoid Arthritis - Treatment Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose:

In the last few year the introduction of biological agents has radically changed  the clinical outcome of patients with Rheumatoid Arthritis (RA). However, no single drug is able to control all patients with RA and it is known that each drug may be poorly effective in a sizable proportion of the treated patients. For these reasons the early identification of clinical responder patients would be a crucial advantage for both a clinical and socioeconomic point of view. Recently, mathematic algorithms, based on classical clinical parameters,  have been proposed  to predict the clinical response to Anti TNF and DMARDs. In the present study we have applied the mathematic algorithm  proposed to predict early response to anti TNF on our cohort of patients treated with antiTNF agents.

Methods: We collected the data of 96 patients followed in our unit and treated with antiTNF (Adalimumab,  Etanercept , Infliximab, Golimumab and Certolizumab  Pegol) from Jan 2010 to Jan 2013, with a follow up of at least 12 months. The mathematic algorithm, utilizing the following parameters: Tender Joint, Swollen Joint, Illness activity VAS by Physician and patient, Pain VAS, ESR and CRP; was applied to calculate the putative responders after one month of treatment and this value was compared with the DAS 28 at one month and after  one year (yr). The patients were classified as good responders if they had a delta DAS28>1.2. In table 1 we summarized  the main epidemiological and  clinical data of patients under investigation.

Results:

The clinical response at 1 yr was very significant for all kind of treatment.  After 1 month of therapy a delta DAS 28>2.6 was recorded in 50% of all treated patients, while at one yr a delta DAS28>1.2 was found in percentage variable between 86% and 91.6% (table1). In contrast, the mathematical model allows to predict 100% of the final responders for patients treated by Infliximab, Golimumab and Certolizumab  Pegol, 93% for patients treated with Adalimumab and 90% with Etanercept, 5 false negative were registered for Etanercept and 3 false negative for Adalimumab.

Conclusion: These data indicate that in a routine clinical practice the application of a simple mathematical model is capable, at one month, to predict a good response in the majority of patients. Prospective studies are underway.

Table 1
Certolizumab Pegol Adalimumab Infliximab Etanercept  Golimumab
Number of  patients 12 25 13 42 4
Age 52.63±15.58 54.76 ± 15.57 58.00 ± 10.30 59.73 ± 15.32 51.21±13.60
Sex 10 ♀ 2 ♂ 21 ♀ 4 ♂ 10 ♀ 3 ♂ 35 ♀ 7 ♂ 2 ♀ 2 ♂
DAS28 at baseline 5.77 ±0.90 5.60 ± 0.89 6.46 ± 1.13 6.24±0.78 5.27 ± 0.61
DAS28 at final visit 1.99 ± 0.43 2.80 ± 1.23 2.75 ± 0.74 3.14 ± 0.96 3.93 ± 0.84

% of Response

Delta DAS28>1.2

91.6 86.0 91.9 88.1 89.4

Disclosure:

C. Giacomelli,
None;

C. Ferrari,
None;

C. Stagnaro,
None;

R. Talarico,
None;

A. Consensi,
None;

F. Sernissi,
None;

L. Bazzichi,
None;

S. Bombardieri,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mathematical-model-to-predict-the-early-responders-in-a-monocentric-cohort-of-patients-with-rheumatoid-arthritis-treated-by-anti-tnf-alpha/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies